Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis
Updated meta-analysis published in Coronary Artery Disease (2023)
Abstract
BACKGROUND: The use of bivalirudin-based anticoagulation over heparin-based anticoagulation for coronary percutaneous intervention has been debated for a long time. Multiple trials have shown promising benefits of bivalirudin over heparin therapy with the most recent addition being the BRIGHT-4 trial. We performed a meta-analysis to assess evidence from these trials, focusing on the coronary intervention of the STEMI population. METHODS: This meta-analysis was performed based on PRISMA guidelines after registering in PROSPERO (CRD42023394701). Databases were searched for relevant articles published before January 2023. Pertinent data from the included studies were extracted and analyzed using RevMan v5.4. RESULTS: Out of 2375 studies evaluated, 13 randomized control trials with 24 360 acute ST-elevation myocardial infarction patients were included for analysis. The bivalirudin-based anticoagulation reduced the net clinical events (OR 0.75, CI 0.61-0.92), major adverse cardiac or cerebral events (OR 0.85, CI 0.74-0.98), any bleeding (OR 0.61, CI 0.45-0.83), major bleeding (OR 0.54, CI 0.39-0.75), all-cause mortality (OR 0.79, CI 0.67-0.92) and cardiac mortality (OR 0.78, CI 0.65-0.93) significantly without increasing the risk of any stent thrombosis (OR 0.92, 95% CI 0.52-1.61), definite stent thrombosis (OR 1.17, 95% CI 0.62-2.22) and acute stent thrombosis (OR 2.06, 95% CI 0.69-6.09) significantly at 30 days. CONCLUSION: Based on this meta-analysis, bivalirudin plus a post-PCI high-dose infusion-based anticoagulation during STEMI PCI has significant benefits over heparin therapy for cardiovascular outcomes without a significant increase in the risk of thrombotic outcomes.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Updated post-BRIGHT-4 STEMI meta-analysis confirming bivalirudin reduces 30-day all-cause mortality and major bleeding in primary PCI versus heparin.
Why This Matters for Hirudotherapy
This updated meta-analysis of 13 randomized controlled trials (24,360 STEMI patients) found that bivalirudin-based anticoagulation during percutaneous coronary intervention significantly reduced net clinical events, major bleeding, all-cause mortality, and cardiac mortality at 30 days versus heparin, without significantly increasing stent thrombosis. Bivalirudin is a synthetic direct thrombin inhibitor modeled on hirudin, the anticoagulant found in medicinal leech saliva, so this large-scale cardiovascular evidence is directly informative to leech-secretome science and illustrates how a leech-derived pharmacological principle translates into mainstream clinical cardiology. For ASH, these findings provide contemporary outcome data on a hirudin analog used widely in interventional medicine. However, the study evaluates a pharmaceutical derivative rather than live leech therapy or the whole leech secretome, and results are limited to short-term 30-day outcomes in a specific cardiac population.
Citation
Bivalirudin versus heparin in STEMI after BRIGHT-4 trial: an updated meta-analysis.
Oli PR et al. · Coronary artery disease, 2023
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026